Policy Effective Date

The policy effective date in insurance is the date on which the policy coverage starts. It is the date from which the policyholder is covered by the insurance policy and can make a claim in case of a covered event.

 

Example: John purchases a car insurance policy from XYZ insurance company on May 1st, 2023. The policy effective date is May 1st, 2023.If John gets into a car accident on May 2nd, 2023, he can make a claim to the insurance company to cover the damages to his car.

 

Key features:

- The policy effective date is the start date of the insurance coverage.

- It is important to pay attention to the policy effective date to ensure that the coverage starts when intended.

- The policy effective date can be different from the date the insurance policy is purchased, depending on the terms of the policy.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.